Medicine Overview
Adult Dose
| Clinical Information | Administration Information |
|---|---|
|
Indication: Chronic lymphocytic leukaemia, Small lymphocytic lymphoma Age: Adult Condition: Dose ramp-up phase Week 1 |
Dose: Oral – 20 mg Frequency: once daily Note: Ramp-up dosing schedule designed to gradually reduce tumor burden and decrease risk of tumor lysis syndrome. |
|
Indication: Chronic lymphocytic leukaemia, Small lymphocytic lymphoma Age: Adult Condition: Dose ramp-up phase Week 2 |
Dose: Oral – 50 mg Frequency: once daily Note: Ramp-up dosing schedule designed to gradually reduce tumor burden and decrease risk of tumor lysis syndrome. |
Child Dose
| Clinical Information | Administration Information |
|---|---|
|
Age: Child |
Dose: Tablet – No approved pediatric dosage available Note: No approved pediatric dosage available |
Renal Dose
| Clinical Information | Administration Information |
|---|---|
|
Condition: Mild or moderate renal impairment (Creatinine Clearance greater than or equal to 15 mL/minute) |
Dose: Not specified Note: No dosage adjustment necessary |
|
Condition: Severe renal impairment (Creatinine Clearance less than 15 mL/minute) or patients on dialysis |
Dose: Not specified Note: Recommended dose has not been determined |
Administration
- Should be taken with food
- Take at same time each day
Side Effect
- (Combination with rituximab) Leukopenia (89%)
- Lymphopenia (87%)
- Neutropenia (65-86%)
- Neutropenia Grade 3 or 4 (62-64%)
- Hypocalcemia (62%)
- Hypophosphatemia (57%)
- Lymphopenia Grade 3 or 4 (56%)
- Leukopenia Grade 3 or 4 (46%)
- Diarrhea (43%)
- Increased AST/SGOT (46%)
- Diarrhea (40%)
- Upper respiratory tract infection (URTI) (39%)
- Hyperuricemia (36%)
- Increased alkaline phosphatase (35%)
- Hyperbilirubinemia (33%)
- Hyponatremia (30%)
- Hypokalemia (29%)
- Hyperkalemia (24%)
- Hypernatremia (24%)
- Nausea (21%)
- Musculoskeletal pain (19%)
- Lower respiratory tract infection (18%)
- Anemia (16%)
- Thrombocytopenia (15%)
- Constipation (14%)
- Hypophosphatemia Grade 3 or 4 (14%)
- Abdominal pain (13%)
- Rash (13%)
- Headache (11%)
- Insomnia (11%)
- (Monotherapy)
- Neutropenia (50%)
- Neutropenia Grade 3 or 4 (45%)
- Nausea (42%)
- Upper respiratory tract infection (URTI) (36%)
- Anemia (33%)
- Fatigue (32%)
- Thrombocytopenia (29%)
- Edema (22%)
- Thrombocytopenia Grade 3 or 4 (20%)
- Anemia Grade 3 or 4 (18%)
- Abdominal pain (18%)
- Pyrexia (18%)
- Vomiting (16%)
- Constipation (16%)
- Mucositis (13%)
- Lymphopenia (11%)
- Mucositis (10%)
- Pneumonia (10%)
- Vomiting (8%)
- Lymphopenia Grade 3 or 4 (7%)
- Hyponatremia Grade 3 or 4 (6%)
- Hypokalemia Grade 3 or 4 (6%)
- Hypocalcemia Grade 3 or 4 (5%)
- Febrile neutropenia (4%)
- Hyperbilirubinemia Grade 3 or 4 (4%)
- Diarrhea Grade 3 or 4 (3%)
- TLS Grade 3 or 4 (3%)
- Hyperkalemia Grade 3 or 4 (3%)
- Upper respiratory tract infection (URTI) Grade 3 or 4 (2%)
- Lower respiratory tract infection Grade 3 or 4 (2%)
- Increased AST/SGOT (2%)
- Hypernatremia Grade 3 or 4 (1%)
- Musculoskeletal pain Grade 3 or 4 (1%)
- Increased alkaline phosphatase Grade 3 or 4 (1%)
- Febrile neutropenia (6%)
- Fatigue Grade 3 or 4 (4%)
- Abdominal pain Grade 3 or 4 (3%)
- Diarrhea Grade 3 or 4 (3%)
- Edema Grade 3 or 4 (2%)
- Nausea Grade 3 or 4 (1%)
- Vomiting Grade 3 or 4 (1%)
- Upper respiratory tract infection (URTI) Grade 3 or 4 (1%)
- Constipation Grade 3 or 4
- Mucositis Grade 3 or 4
- Pyrexia Grade 3 or 4
Drug Interaction
Drug Interaction
| Drug Name | Risk Factors |
|---|---|
|
Moderate to strong CYP3A4 inducers (e.g. carbamazepine, phenytoin, rifampicin)
|
Decreased serum concentration and efficacy
|
|
Strong CYP3A4 inhibitors (e.g. itraconazole, clarithromycin, ritonavir)
|
Potentially Fatal: Increased serum concentration and risk of TLS
|
Disease Interaction
Disease Interaction
| Disease Name | Risk Factors |
|---|---|
|
No specific contraindications listed
|
Monitor for general drug reactions
|
Pregnancy
Pregnancy
Lactation
Special Use
Precaution
Overdose
Pharmacology
Storage
Details coming soon
Data Sources
Clinical & regulatory information on this page is compiled from the following government sources:
DISCLAIMER: This drug information content is provided for informational purposes only and is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Patients should always consult their physician with any questions regarding a medical condition and to obtain medical advice and treatment.